Biomarker tests for molecularly targeted therapies need better evidence, oversight
Friday, March 4, 2016 - 14:00
in Health & Medicine
Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions, says a new report.